Stock Traders Purchase Large Volume of BioNTech Call Options (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) was the recipient of some unusual options trading activity on Tuesday. Stock traders purchased 4,599 call options on the company. This represents an increase of 58% compared to the average daily volume of 2,906 call options.

BioNTech Trading Up 5.5 %

NASDAQ:BNTX opened at $126.88 on Wednesday. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The business has a 50 day simple moving average of $113.72 and a 200 day simple moving average of $102.79. The firm has a market capitalization of $30.42 billion, a P/E ratio of -60.42 and a beta of 0.18.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter last year, the company earned $0.73 EPS. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities research analysts predict that BioNTech will post -3.72 EPS for the current year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of BNTX. FMR LLC raised its position in BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after acquiring an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC bought a new stake in shares of BioNTech in the 3rd quarter worth approximately $59,485,000. Point72 Asset Management L.P. raised its holdings in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after purchasing an additional 341,311 shares in the last quarter. Braidwell LP acquired a new stake in BioNTech during the third quarter valued at approximately $29,425,000. Finally, New York State Common Retirement Fund boosted its holdings in BioNTech by 457.9% during the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock worth $25,900,000 after buying an additional 178,981 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. UBS Group boosted their target price on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Berenberg Bank began coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price on the stock. JPMorgan Chase & Co. lowered their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Finally, Bank of America increased their target price on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $140.76.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.